Further specialized experiments must prove in how far SP inhibition could be used as therapeutic means to alleviate the deleterious effects of SP-dependent neurogenic mechanism on renal disease not only in mere inflammation but perhaps also in arterial hypertension. This evidence concerns the gene TFF2 and kidney disorder.